EE200300052A - Kolesterüülestri ülekandevalgu inhibiitorite farmatseutilised kompositsioonid - Google Patents

Kolesterüülestri ülekandevalgu inhibiitorite farmatseutilised kompositsioonid

Info

Publication number: EE200300052A
Authority: EE; Estonia
Prior art keywords: pharmaceutical compositions; transfer protein; cholesteryl ester; protein inhibitors; ester transfer
Prior art date: 2000-08-03

Application number

EEP200300052A

Other languages

English (en)

Estonian (et)

Inventor

John Curatolo William

Thomas Friesen Dwayne

Jon Gumkowski Michael

Alan Lorenz Douglas

Alan Schriver Nightingale James

Benjamin Ruggeri Roger

Mysore Shanker Ravi

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-03

Filing date

2001-07-31

Publication date

2004-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22835821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200300052(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-07-31 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2004-12-15 Publication of EE200300052A publication Critical patent/EE200300052A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

EEP200300052A 2000-08-03 2001-07-31 Kolesterüülestri ülekandevalgu inhibiitorite farmatseutilised kompositsioonid EE200300052A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22327900P	2000-08-03	2000-08-03
PCT/IB2001/001391 WO2002011710A2 (en)	2000-08-03	2001-07-31	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors

Publications (1)

Publication Number	Publication Date
EE200300052A true EE200300052A (et)	2004-12-15

Family

ID=22835821

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300052A EE200300052A (et)	2000-08-03	2001-07-31	Kolesterüülestri ülekandevalgu inhibiitorite farmatseutilised kompositsioonid

Country Status (39)

Country	Link
US (4)	US7115279B2 (xx)
EP (2)	EP1305007B1 (xx)
JP (2)	JP2004505911A (xx)
KR (1)	KR100561572B1 (xx)
CN (1)	CN1458840A (xx)
AP (1)	AP2001002235A0 (xx)
AR (1)	AR030570A1 (xx)
AT (1)	ATE503462T1 (xx)
AU (1)	AU2914202A (xx)
BG (1)	BG107456A (xx)
BR (1)	BR0112828A (xx)
CA (1)	CA2417755A1 (xx)
CR (1)	CR6883A (xx)
CZ (1)	CZ2003224A3 (xx)
DE (1)	DE60144332D1 (xx)
DO (1)	DOP2001000224A (xx)
DZ (1)	DZ3391A1 (xx)
EA (1)	EA007013B1 (xx)
EC (1)	ECSP034462A (xx)
EE (1)	EE200300052A (xx)
GT (1)	GT200100156A (xx)
HN (1)	HN2001000175A (xx)
HU (1)	HUP0300676A2 (xx)
IL (1)	IL154017A0 (xx)
IS (1)	IS6688A (xx)
MA (1)	MA26935A1 (xx)
MX (1)	MXPA03001035A (xx)
NO (1)	NO20030506L (xx)
NZ (1)	NZ523680A (xx)
OA (1)	OA12350A (xx)
PA (1)	PA8523901A1 (xx)
PE (1)	PE20020271A1 (xx)
PL (1)	PL365168A1 (xx)
SK (1)	SK1032003A3 (xx)
SV (1)	SV2002000581A (xx)
TN (1)	TNSN01119A1 (xx)
UY (1)	UY26864A1 (xx)
WO (1)	WO2002011710A2 (xx)
ZA (1)	ZA200300869B (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7115279B2 (en) *	2000-08-03	2006-10-03	Curatolo William J	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
DE10063486A1 (de) *	2000-12-20	2002-07-04	Bayer Ag	Dichlorpyridylmethylamide
JP2005500314A (ja) *	2001-06-21	2005-01-06	ファイザー・プロダクツ・インク	コレステロールエステル転送蛋白インヒビターの自己乳化性製剤
PL368587A1 (en) *	2001-06-22	2005-04-04	Pfizer Products Inc.	Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
CZ20033456A3 (en) *	2001-06-22	2004-07-14	Pfizer Products Inc.	Pharmaceutical compositions comprising adsorbates of amorphous drug
CA2448864C (en) *	2001-06-22	2008-04-22	Pfizer Products Inc.	Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
EP1401399A2 (en) *	2001-06-22	2004-03-31	Pfizer Products Inc.	Pharmaceutical compositions containing polymer and drug assemblies
WO2003000235A1 (en)	2001-06-22	2003-01-03	Pfizer Products Inc.	Pharmaceutical compositions of dispersions of drugs and neutral polymers
MXPA04007428A (es)	2002-02-01	2004-10-11	Pfizer Prod Inc	Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido.
ATE395044T1 (de)	2002-02-01	2008-05-15	Pfizer Prod Inc	Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
AR038375A1 (es) *	2002-02-01	2005-01-12	Pfizer Prod Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
PL372247A1 (en)	2002-02-01	2005-07-11	Pfizer Products Inc.	Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
CA2473991C (en)	2002-02-01	2009-09-15	Pfizer Products Inc.	Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
PL371593A1 (en) *	2002-02-01	2005-06-27	Pfizer Products Inc.	Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
ES2333318T3 (es)	2002-08-12	2010-02-19	Bend Research, Inc.	Composiciones farmaceuticas de medicamentos con estructura semiordenada y de polimero.
US7504508B2 (en)	2002-10-04	2009-03-17	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en)	2002-10-04	2005-12-27	Millennium Pharmaceuticals, Inc.	Pgd2 receptor antagonists for the treatment of inflammatory diseases
JP2006512359A (ja) *	2002-12-20	2006-04-13	ファイザー・プロダクツ・インク	ＣＥＴＰ阻害薬及びＨＭＧ−ＣｏＡ還元酵素阻害薬を含有する剤形
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
JP2006513186A (ja)	2002-12-20	2006-04-20	ファイザー・プロダクツ・インク	Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
ZA200508160B (en) *	2003-03-17	2007-01-31	Japan Tobacco Inc	Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl) 2-methyl-propanethioate
ES2377121T3 (es)	2003-03-17	2012-03-22	Japan Tobacco Inc.	Composiciones farmacéuticas de inhibidores de CETP
WO2004082675A1 (en) *	2003-03-17	2004-09-30	Japan Tobacco Inc.	Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CN1863511A (zh) *	2003-08-04	2006-11-15	辉瑞产品公司	提供控制释放的胆固醇酯转移蛋白抑制剂以及立即释放的HMG－CoA还原酶抑制剂的剂型
MXPA06001417A (es) *	2003-08-04	2006-05-15	Pfizer Prod Inc	Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
CL2004001884A1 (es) *	2003-08-04	2005-06-03	Pfizer Prod Inc	Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
KR20060080214A (ko)	2003-09-26	2006-07-07	니뽄 다바코 산교 가부시키가이샤	잔여 리포프로테인 생산 저해 방법
MXPA06003499A (es) *	2003-09-30	2006-06-08	Pfizer Prod Inc	Inhibidores de proteina de transferencia de esteres de colestrerilo y sus metabolitos.
US7749992B2 (en) *	2003-10-08	2010-07-06	Eli Lilly And Company	Compounds and methods for treating dislipidemia
ES2320770T3 (es) *	2004-05-26	2009-05-28	Arturo Jimenez Bayardo	Metodo de preparacion de una solucion oftalmica de latanoprost y la solucion asi producida.
WO2006069162A1 (en)	2004-12-20	2006-06-29	Reddy Us Therapeutics, Inc.	Novel heterocyclic compounds and their pharmaceutical compositions
MX2007007919A (es)	2004-12-31	2008-01-22	Reddy Us Therapeutics Inc	Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
US8604055B2 (en)	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2601762A1 (en) *	2005-02-03	2006-08-10	Pfizer Products Inc.	Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006091674A1 (en)	2005-02-24	2006-08-31	Millennium Pharmaceuticals, Inc.	Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20070178152A1 (en) *	2005-11-04	2007-08-02	Shelton Michael C	Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
KR101418267B1 (ko) *	2006-02-09	2014-07-11	머크 샤프 앤드 돔 코포레이션	Ｃｅｔｐ 억제제의 중합체 제형
PE20081506A1 (es) *	2006-12-12	2008-12-09	Infinity Discovery Inc	Formulaciones de ansamicina
EP1997819A1 (de)	2007-05-25	2008-12-03	Boehringer Ingelheim Pharma GmbH & Co. KG	Verfahren zur Herstellung von Scopinestern
US8337835B2 (en) *	2009-04-10	2012-12-25	Washington University	Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders
SMT202000093T1 (it)	2009-06-16	2020-03-13	Pfizer	Forme di dosaggio di apixaban
EP2675434A1 (en)	2011-02-17	2013-12-25	F.Hoffmann-La Roche Ag	A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
US8591944B2 (en)	2011-03-08	2013-11-26	Zalicus Pharmaceuticals Ltd.	Solid dispersion formulations and methods of use thereof
WO2013024358A2 (en)	2011-08-18	2013-02-21	Dr. Reddy's Laboratories Ltd.	Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
KR101803866B1 (ko)	2011-09-27	2017-12-04	닥터 레디스 레보러터리즈 리미티드	동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
US20170071930A1 (en) *	2012-11-19	2017-03-16	Dr. Reddy's Laboratories Ltd.	Pharmaceutical compositions of cetp inhibitors

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3871866D1 (de)	1987-07-17	1992-07-16	Dow Corning	Haertbare zusammensetzung.
JP2528706B2 (ja) *	1988-05-30	1996-08-28	ゼリア新薬工業株式会社	ジヒドロピリジン化合物の製剤組成物
US5093371A (en) *	1990-07-02	1992-03-03	University Of Iowa Research Foundation	Naphthyl ketone inhibitors of cholesterol esterase and their use as hypolipidemic and hypocaloric agents
ES2111065T5 (es)	1991-04-16	2005-06-16	Nippon Shinyaku Company, Limited	Procedimiento para producir una dispersion solida.
US5340591A (en) *	1992-01-24	1994-08-23	Fujisawa Pharmaceutical Co., Ltd.	Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5446207A (en) *	1993-09-01	1995-08-29	Harbor Branch Oceanographic Institution, Inc.	Anti-dyslipidemic agents
US5474993A (en) *	1994-06-14	1995-12-12	Sterling Winthrop, Inc.	Lactam inhibitors of cholesterol esterase
US5880095A (en)	1994-11-12	1999-03-09	Lg Chemical Ltd.	Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents
WO1996019239A1 (en) *	1994-12-21	1996-06-27	Yamanouchi Pharmaceutical Co., Ltd.	Solid composition with improved solubility and absorbability
TW487582B (en) *	1995-08-11	2002-05-21	Nissan Chemical Ind Ltd	Method for converting sparingly water-soluble medical substance to amorphous state
GB2305665A (en) *	1995-09-26	1997-04-16	Merck & Co Inc	Selective ß3 agonists for the treatment of diabetes aand obesity
DE19610932A1 (de)	1996-03-20	1997-09-25	Bayer Ag	2-Aryl-substituierte Pyridine
EP0801060A1 (en)	1996-04-09	1997-10-15	Pfizer Inc.	Heterocyclic Beta-3 Adrenergenic Agonists
HRP970330B1 (en)	1996-07-08	2004-06-30	Bayer Ag	Cycloalkano pyridines
DE19627431A1 (de)	1996-07-08	1998-01-15	Bayer Ag	Heterocyclisch kondensierte Pyridine
AR008789A1 (es)	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
JP3290962B2 (ja) *	1997-02-12	2002-06-10	日本たばこ産業株式会社	Ｃｅｔｐ活性阻害剤
JP2894445B2 (ja) *	1997-02-12	1999-05-24	日本たばこ産業株式会社	Ｃｅｔｐ活性阻害剤として有効な化合物
DE19709125A1 (de)	1997-03-06	1998-09-10	Bayer Ag	Substituierte Chinoline
JPH10287662A (ja)	1997-04-08	1998-10-27	Kitasato Inst:The	Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
ATE270284T1 (de) *	1997-04-16	2004-07-15	Univ New Mexico	Cholesterin esterase inhibitoren
US5955475A (en) *	1997-06-30	1999-09-21	Endo Pharmaceuticals Inc.	Process for manufacturing paroxetine solid dispersions
EP0901786B1 (en) *	1997-08-11	2007-06-13	Pfizer Products Inc.	Solid pharmaceutical dispersions with enhanced bioavailability
AU9297798A (en)	1997-09-16	1999-04-05	G.D. Searle & Co.	Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19741051A1 (de)	1997-09-18	1999-03-25	Bayer Ag	Hetero-Tetrahydrochinoline
MA24643A1 (fr)	1997-09-18	1999-04-01	Bayer Ag	Tetrahydro-naphtalenes substitues et composes analogues
DE19741399A1 (de) *	1997-09-19	1999-03-25	Bayer Ag	Tetrahydrochinoline
AU3285499A (en)	1998-02-13	1999-08-30	G.D. Searle & Co.	Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
JP3433417B2 (ja) *	1998-04-02	2003-08-04	トヨタ自動車株式会社	レーダ装置
DK1083885T3 (da) *	1998-06-11	2007-02-26	Pharmacia & Upjohn Co Llc	Delavirdintabletformulering
US6140342A (en) *	1998-09-17	2000-10-31	Pfizer Inc.	Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en)	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) *	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
JP2002525350A (ja)	1998-09-25	2002-08-13	モンサントカンパニー	コレステロールエステル輸送タンパク質活性阻害に有効な置換されたｎ−脂肪族−ｎ−芳香族第三級ヘテロアルキルアミン
EP1115695B1 (en)	1998-09-25	2005-06-01	Monsanto Company	(r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
ATE400252T1 (de)	1999-02-10	2008-07-15	Pfizer Prod Inc	Pharmazeutische feste dispersionen
US6706283B1 (en) *	1999-02-10	2004-03-16	Pfizer Inc	Controlled release by extrusion of solid amorphous dispersions of drugs
DE69932746D1 (de)	1999-03-08	2006-09-21	Kitasato Inst	SUBSTANZEN WK-5344A UND Wk-5344B UND VERFAHREN ZUR HERSTELLUNG DERSELBEN
US6465011B2 (en)	1999-05-29	2002-10-15	Abbott Laboratories	Formulations comprising lipid-regulating agents
US20010018446A1 (en)	1999-09-23	2001-08-30	G.D. Searle & Co.	Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
CO5271716A1 (es)	1999-11-30	2003-04-30	Pfizer Prod Inc	Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
EP1967185A1 (en) *	1999-12-23	2008-09-10	Pfizer Products Inc.	Hydrogel-driven drug dosage form
WO2001056579A1 (en)	2000-02-04	2001-08-09	Esperion Therapeutics Inc.	Methods for treating alzheimer's disease
US7115279B2 (en) *	2000-08-03	2006-10-03	Curatolo William J	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1401399A2 (en) *	2001-06-22	2004-03-31	Pfizer Products Inc.	Pharmaceutical compositions containing polymer and drug assemblies
PL368587A1 (en) *	2001-06-22	2005-04-04	Pfizer Products Inc.	Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
WO2003000235A1 (en) *	2001-06-22	2003-01-03	Pfizer Products Inc.	Pharmaceutical compositions of dispersions of drugs and neutral polymers
AR038375A1 (es) *	2002-02-01	2005-01-12	Pfizer Prod Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
PL372247A1 (en) *	2002-02-01	2005-07-11	Pfizer Products Inc.	Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
JP2006512359A (ja) *	2002-12-20	2006-04-13	ファイザー・プロダクツ・インク	ＣＥＴＰ阻害薬及びＨＭＧ−ＣｏＡ還元酵素阻害薬を含有する剤形

2001
- 2001-07-30 US US09/918,127 patent/US7115279B2/en not_active Expired - Fee Related
- 2001-07-31 WO PCT/IB2001/001391 patent/WO2002011710A2/en not_active Ceased
- 2001-07-31 HU HU0300676A patent/HUP0300676A2/hu unknown
- 2001-07-31 CN CN01815834A patent/CN1458840A/zh active Pending
- 2001-07-31 PL PL01365168A patent/PL365168A1/xx unknown
- 2001-07-31 DZ DZ013391A patent/DZ3391A1/xx active
- 2001-07-31 SV SV2001000581A patent/SV2002000581A/es not_active Application Discontinuation
- 2001-07-31 AU AU2914202A patent/AU2914202A/xx not_active Withdrawn
- 2001-07-31 EA EA200300073A patent/EA007013B1/ru not_active IP Right Cessation
- 2001-07-31 DE DE60144332T patent/DE60144332D1/de not_active Expired - Lifetime
- 2001-07-31 SK SK103-2003A patent/SK1032003A3/sk not_active Application Discontinuation
- 2001-07-31 OA OA1200300022A patent/OA12350A/en unknown
- 2001-07-31 BR BR0112828-0A patent/BR0112828A/pt not_active IP Right Cessation
- 2001-07-31 KR KR1020037001456A patent/KR100561572B1/ko not_active Expired - Fee Related
- 2001-07-31 NZ NZ523680A patent/NZ523680A/en unknown
- 2001-07-31 EP EP01984472A patent/EP1305007B1/en not_active Expired - Lifetime
- 2001-07-31 JP JP2002517047A patent/JP2004505911A/ja active Pending
- 2001-07-31 EE EEP200300052A patent/EE200300052A/xx unknown
- 2001-07-31 MX MXPA03001035A patent/MXPA03001035A/es active IP Right Grant
- 2001-07-31 CA CA002417755A patent/CA2417755A1/en not_active Abandoned
- 2001-07-31 AT AT01984472T patent/ATE503462T1/de not_active IP Right Cessation
- 2001-07-31 IL IL15401701A patent/IL154017A0/xx unknown
- 2001-07-31 CZ CZ2003224A patent/CZ2003224A3/cs unknown
- 2001-07-31 EP EP20100180614 patent/EP2258352B1/en not_active Expired - Lifetime
- 2001-08-01 DO DO2001P000224A patent/DOP2001000224A/es unknown
- 2001-08-01 UY UY26864A patent/UY26864A1/es not_active Application Discontinuation
- 2001-08-01 GT GT200100156A patent/GT200100156A/es unknown
- 2001-08-02 TN TNTNSN01119A patent/TNSN01119A1/fr unknown
- 2001-08-02 AR ARP010103694A patent/AR030570A1/es unknown
- 2001-08-02 AP APAP/P/2001/002235A patent/AP2001002235A0/en unknown
- 2001-08-02 PE PE2001000773A patent/PE20020271A1/es not_active Application Discontinuation
- 2001-08-03 PA PA20018523901A patent/PA8523901A1/es unknown
- 2001-08-06 HN HN2001000175A patent/HN2001000175A/es unknown
2003
- 2003-01-13 BG BG107456A patent/BG107456A/bg unknown
- 2003-01-16 IS IS6688A patent/IS6688A/is unknown
- 2003-01-16 CR CR6883A patent/CR6883A/es not_active Application Discontinuation
- 2003-01-23 MA MA27010A patent/MA26935A1/fr unknown
- 2003-01-31 ZA ZA200300869A patent/ZA200300869B/en unknown
- 2003-01-31 NO NO20030506A patent/NO20030506L/no not_active Application Discontinuation
- 2003-02-03 EC EC2003004462A patent/ECSP034462A/es unknown
2006
- 2006-06-02 US US11/421,888 patent/US8048452B2/en not_active Expired - Fee Related
2007
- 2007-04-30 US US11/799,447 patent/US8197848B2/en not_active Expired - Fee Related
- 2007-08-09 JP JP2007208058A patent/JP2007314573A/ja active Pending
2012
- 2012-06-12 US US13/494,668 patent/US8389011B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MA26935A1 (fr)	2004-12-20
EP1305007B1 (en)	2011-03-30
NO20030506D0 (no)	2003-01-31
IS6688A (is)	2003-01-16
ECSP034462A (es)	2003-03-31
US8389011B2 (en)	2013-03-05
CA2417755A1 (en)	2002-02-14
BG107456A (bg)	2003-09-30
EP2258352B1 (en)	2015-05-13
EP2258352A2 (en)	2010-12-08
AP2001002235A0 (en)	2001-09-30
DE60144332D1 (de)	2011-05-12
DOP2001000224A (es)	2002-06-15
CN1458840A (zh)	2003-11-26
US20070282009A1 (en)	2007-12-06
EP2258352A3 (en)	2013-08-14
ZA200300869B (en)	2004-04-16
UY26864A1 (es)	2002-02-28
AR030570A1 (es)	2003-08-27
US20020103225A1 (en)	2002-08-01
CZ2003224A3 (cs)	2004-02-18
US7115279B2 (en)	2006-10-03
PL365168A1 (en)	2004-12-27
NO20030506L (no)	2003-01-31
MXPA03001035A (es)	2003-05-27
WO2002011710A3 (en)	2002-05-02
SV2002000581A (es)	2002-10-24
WO2002011710A2 (en)	2002-02-14
EA007013B1 (ru)	2006-06-30
PA8523901A1 (es)	2002-04-25
US8048452B2 (en)	2011-11-01
IL154017A0 (en)	2003-07-31
JP2004505911A (ja)	2004-02-26
GT200100156A (es)	2002-04-23
EA200300073A1 (ru)	2003-08-28
CR6883A (es)	2003-11-25
US20060211654A1 (en)	2006-09-21
JP2007314573A (ja)	2007-12-06
US8197848B2 (en)	2012-06-12
OA12350A (en)	2006-05-16
KR100561572B1 (ko)	2006-03-16
EP1305007A2 (en)	2003-05-02
ATE503462T1 (de)	2011-04-15
HUP0300676A2 (hu)	2003-08-28
PE20020271A1 (es)	2002-04-08
HN2001000175A (es)	2001-10-08
TNSN01119A1 (fr)	2005-11-10
KR20030026995A (ko)	2003-04-03
AU2914202A (en)	2002-02-18
SK1032003A3 (en)	2004-05-04
DZ3391A1 (fr)	2002-02-14
US20120277315A1 (en)	2012-11-01
NZ523680A (en)	2004-09-24
BR0112828A (pt)	2003-07-01

Publication	Publication Date	Title
EE200300052A (et)	2004-12-15	Kolesterüülestri ülekandevalgu inhibiitorite farmatseutilised kompositsioonid
EE200400024A (et)	2004-06-15	Kolesterüülestri ülekandevalgu inhibiitorite iseemulgeeruvad formulatsioonid
DK1105122T3 (da)	2005-08-08	Pharmaceutical compositions containing lipase inhibitors
NO20043506L (no)	2004-10-19	Kontrollert frigivende farmasoytiske doseringsformer av en kolesterylester overforingsproteininhibitor
EE200200530A (et)	2004-04-15	Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid
EE200200393A (et)	2003-10-15	Glüburiidi ravimkoostis
AR028204A1 (es)	2003-04-30	Composiciones farmaceuticas electrohiladas
FI20105657L (fi)	2010-06-10	Farmaseuttisia koostumuksia
ITMI20010748A0 (it)	2001-04-06	Composizioni farmaceutiche
PT1105123E (pt)	2004-08-31	Composicoes farmaceuticas contendo inibidores da lipase e quitosano
NO20014893L (no)	2001-11-15	Farmasoytiske sammensetninger av erythropoietin
NO20026123L (no)	2003-02-18	Farmasöytiske sammensetninger
EE200100611A (et)	2003-02-17	NOS inhibiitorite uued farmatseutilised kombinatsioonid
NO20031095D0 (no)	2003-03-10	Farmasöytiske sammensetninger
SI1475379T1 (sl)	2007-08-31	Uporaba derivatov skopinskega estra za pripravo zdravil
EE200300468A (et)	2004-02-16	Pravastatiini stabiilne farmatseutiline kompositsioon
EE200100084A (xx)	2002-08-15	NOS inhibiitorite uued farmatseutilised kasutusv�imalused
EE200200429A (et)	2003-12-15	Kolesteroolestri ja vahaestri sünteesi duaalsed inhibiitorid rasunäärme häirete jaoks
ITMI20000554A0 (it)	2000-03-17	Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono
EE200200689A (et)	2004-06-15	Ravimkoostised
SE0000934D0 (sv)	2000-03-21	Method of preparing pharmaceutical compositions
IDP000026456A (id)	2001-08-02	Senyawa-senyawa siklopropanakarboksilat ester
ITMI20000360A0 (it)	2000-02-25	Gel orale contenente composti aminoacidi solforati